See the article here:

LAVA Therapeutics Announces Selection by Janssen of Lead Gamma-Delta T-Cell Engager Bispecific Antibody to Move Toward Clinical Development

Related Post

Leave a comment

Your email address will not be published. Required fields are marked *


Refresh